|
Exempt Distribution - 2022-04-14
|
2
|
Resverlogix Corp.
|
Apr 17, 2022 07:34PM
|
|
Exempt Distribution - November 16, 2022
|
3
|
Zenith Epigenetics
|
Dec 06, 2022 12:32PM
|
|
Exempt Distribution 45-106F1
|
1
|
Resverlogix Corp.
|
Mar 13, 2020 02:54PM
|
|
Exempt Distribution 45-106F1
|
7
|
Resverlogix Corp.
|
Mar 27, 2020 12:44PM
|
|
Exempt Distribution October 26, 2022
|
1
|
Zenith Epigenetics
|
Oct 30, 2022 06:40PM
|
|
Exempt Distribution- 2021-03-23
|
3
|
Resverlogix Corp.
|
Mar 24, 2021 02:46PM
|
|
Exempt Distribution- 2021-04-12
|
5
|
Resverlogix Corp.
|
Apr 14, 2021 11:18AM
|
|
Exempt Distributions - Dec 9, 2022 & Jan 13, 2023
|
3
|
Zenith Epigenetics
|
Jan 18, 2023 04:54PM
|
|
Extracorporeal membrane oxygenation
|
2
|
Resverlogix Corp.
|
Apr 01, 2021 09:23AM
|
|
FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
5
|
Resverlogix Corp.
|
Apr 05, 2022 10:37AM
|
|
Financial Reporting Dec 31, 2021 + MD&A now on SEDAR
|
5
|
Resverlogix Corp.
|
Apr 01, 2022 05:47AM
|
|
Financial Statement Q2, 2023 /MD&A
|
2
|
Resverlogix Corp.
|
Aug 12, 2023 08:50AM
|
|
Financials / MD&A - Sept 30, 2022
|
|
Resverlogix Corp.
|
Nov 12, 2022 09:03AM
|
|
Financials/MD&A -SEDAR June 30/22
|
2
|
Resverlogix Corp.
|
Aug 13, 2022 08:49AM
|
|
For The Record
|
6
|
Zenith Epigenetics
|
Sep 28, 2022 06:58AM
|
|
Form 45-106F1 Report of Exempt Distribution Dec 13, 2021
|
2
|
Resverlogix Corp.
|
Dec 14, 2021 06:21AM
|
|
Funds
|
1
|
Resverlogix Corp.
|
Feb 17, 2023 10:31AM
|
|
GCFF: Global Chinese Financial Forum
|
3
|
Resverlogix Corp.
|
Aug 23, 2020 01:52PM
|
|
google
|
2
|
Zenith Epigenetics
|
Sep 21, 2020 09:24AM
|
|
Heart Failure
|
3
|
Resverlogix Corp.
|
Apr 04, 2020 12:50PM
|
